If you're new here, you may want to subscribe to my RSS feed. Thanks for visiting!
New research shows that a new drug called an aromatase inhibitor may boost the survival rate of post menopausal women who suffer from breast cancer. It has show to be a good improvement over the current tamoxifen therapy.
The new drug called Tykerb, couple with chemotherapy, has show in clinical trials to do a better job of fighting breast cancer than chemo alone.
This was a large study and it backs up other reports which also seem to show a benefit from Raloxifene in terms of breast cancer in women after the menopause. The latter point here may be important - after the menopause.
According the HealthDay News, Tamoxifen has been in widespread use among breast cancer survivors for the last two decades. The drug is typically taken after surgery, because it targets the hormone estrogen, which can promote tumor cell growth in women with estrogen-sensitive breast cancer. A standard five-year treatment of tamoxifen has been found to reduce breast cancer death rates by as much as 31 percent.
Tamoxifen must still undergo many tests and trials before it will even be considered for approval. But it is definitely a step in the right direction not to just find a new better cure, but to also realize where our current treatments fall short.
